Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Diphenhydramine × Head & Neck × Clear all

Phase

Phase 3 1 Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 5 Lymphoid 5 Other hematologic neoplasm 3 Genitourinary 3 Thoracic 2 Tumor-Agnostic 1 Sarcoma 1 Other 1 Myeloid 1 Head & Neck 1 Gynecologic 1 Gastrointestinal 1 Dermatologic 1 CNS 1 Breast 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1

Interventions

Cisplatin 276 Radiotherapy 122 pembrolizumab 117 Cetuximab 116 Docetaxel 110 Carboplatin 106 Paclitaxel 86 Fluorouracil 85 Radiotherapy, Intensity-Modulated 84 Nivolumab 51 Gemcitabine 45 toripalimab 41 Radiation 40 Capecitabine 36 Drug Therapy 33 Magnetic Resonance Spectroscopy 29 camrelizumab 28 Surgical Procedures, Operative 28 apatinib 26 130-nm albumin-bound paclitaxel 25 tislelizumab 23 Bevacizumab 23 durvalumab 22 Chemoradiotherapy 22 Specimen Handling 21 nimotuzumab 20 Biopsy 19 Albumin-Bound Paclitaxel 19 sintilimab 18 lenvatinib 18

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03107182 2025-05-06

OPTIMA-II

University of Chicago

Phase 2 Completed

72 enrolled 14 charts

Squamous Cell Carcinoma of Head and Neck

Data powered by HemOnc (CC BY 4.0) Colophon ⚡